 SAN DIEGO, April 8, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced that it will host a key opinion leader KOL webinar on onvansertib for the treatment of KRAS-mutated metastatic colorectal cancer on Monday, April 12, 2021 at 11 a.m. Eastern Time. 